Drugs / DeltaRex-G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04378244 | Dec 2022 → Dec 2023 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome | Aveni Foundation | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DeltaRex-G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04378244 ↗ |
| Action | Inhibit | “DeltaRex-G is a disease-seeking retrovector encoding a cytocidal dominant negative human cyclin G1 as genetic payload.” NCT04378244 ↗ |
| Route | Intravenous | “When injected intravenously, the DeltaRex-G nanoparticles has a navigational system” NCT04378244 ↗ |